Marilena Vrana Reflects on A Year of Growth, Gratitude, and Collective Strength
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, shared on LinkedIn:
”As the year draws to a close, it offers a natural moment to step back and acknowledge the growth, challenges, and progress that have shaped these past months.
Transitions in leadership are rarely seamless, and stepping into this new role mid-year came with a steep learning curve.
Yet through the transition came a clear lesson: leadership isn’t about having all the answers, but about creating the conditions where collaboration, curiosity, and courage can truly thrive.
This year showed again that resilience is built through collective effort.
The challenges we faced became catalysts for reimagining what’s possible, and our achievements became shared wins that strengthened the sense of purpose across the team, our membership, and the broader community of plasma and plasma-derived medicines.
What has truly fueled me throughout the year is the unwavering dedication of the PPTA Europe staff and members.
Your commitment to the mission, your integrity, and your persistence have shaped not only the milestones we reached, but also the “one-team” culture that continues to take root – grounded in trust, transparency, and shared responsibility.
As the year ends, I am deeply grateful for every colleague, partner, and supporter who contributed to this progress.
Thank you for your patience as I found my footing, for the feedback that sharpened our focus, and for the belief in what we’re building together.
In many ways, I’ve grown not just as a leader, but as a listener, a learner, and a teammate.
The year ahead holds promise with new opportunities, renewed momentum, and continued collaboration.
Here’s to building on this foundation together in the coming year, with purpose and optimism.”
Stay updated with Hemostasis Today.
-
Jan 16, 2026, 13:15Paul Bolaji Invites You to Join World Stroke Organization Membership
-
Jan 16, 2026, 12:59Prithu Sundd on The Role of CD39 Polymorphism in Enabling Pulmonary Thrombosis in SCD
-
Jan 16, 2026, 12:46Gregory Piazza on The Effect of Enduring Risk Factors in Provoked VTE
-
Jan 16, 2026, 12:33Fernando Corrales-Medina on Heavy Periods in Teens: Don’t Miss a Bleeding Disorder
-
Jan 16, 2026, 06:05Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
-
Jan 16, 2026, 05:52Piotr Czempik Shares His Latest Contribution to Acta Haematologica Polonic
-
Jan 16, 2026, 05:44Florian Piekarski on Perioperative Blood Management When Allogeneic Transfusion is Not Aaccepted
-
Jan 16, 2026, 05:00Plaque Rupture and Thrombosis
-
Jan 16, 2026, 04:52Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor